Selected article for: "death risk and high dose"
Author: Suarez-Cuartin, Guillermo; Gasa, Merce; Bermudo, Guadalupe; Ruiz, Yolanda; Hernandez-Argudo, Marta; Marin, Alfredo; Trias-Sabria, Pere; Cordoba, Ana; Cuevas, Ester; Sarasate, Mikel; Ariza, Albert; Sabater, Joan; Romero, Nuria; Subirana, Cristina; Molina-Molina, Maria; Santos, Salud
Title: Clinical Outcomes of Severe COVID-19 Patients Admitted to an Intermediate Respiratory Care Unit
  • Cord-id: sgfi0m93
  • Document date: 2021_7_1
    • ID: sgfi0m93
    Snippet: Introduction: Many severe COVID-19 patients require respiratory support and monitoring. An intermediate respiratory care unit (IMCU) may be a valuable element for optimizing patient care and limited health-care resources management. We aim to assess the clinical outcomes of severe COVID-19 patients admitted to an IMCU. Methods: Observational, retrospective study including patients admitted to the IMCU due to COVID-19 pneumonia during the months of March and April 2020. Patients were stratified b
    Document: Introduction: Many severe COVID-19 patients require respiratory support and monitoring. An intermediate respiratory care unit (IMCU) may be a valuable element for optimizing patient care and limited health-care resources management. We aim to assess the clinical outcomes of severe COVID-19 patients admitted to an IMCU. Methods: Observational, retrospective study including patients admitted to the IMCU due to COVID-19 pneumonia during the months of March and April 2020. Patients were stratified based on their requirement of transfer to the intensive care unit (ICU) and on survival status at the end of follow-up. A multivariable Cox proportional hazards method was used to assess risk factors associated with mortality. Results: A total of 253 patients were included. Of them, 68% were male and median age was 65 years (IQR 18 years). Ninety-two patients (36.4%) required ICU transfer. Patients transferred to the ICU had a higher mortality rate (44.6 vs. 24.2%; p < 0.001). Multivariable proportional hazards model showed that age ≥65 years (HR 4.14; 95%CI 2.31–7.42; p < 0.001); chronic respiratory conditions (HR 2.34; 95%CI 1.38–3.99; p = 0.002) and chronic kidney disease (HR 2.96; 95%CI 1.61–5.43; p < 0.001) were independently associated with mortality. High-dose systemic corticosteroids followed by progressive dose tapering showed a lower risk of death (HR 0.15; 95%CI 0.06–0.40; p < 0.001). Conclusions: IMCU may be a useful tool for the multidisciplinary management of severe COVID-19 patients requiring respiratory support and non-invasive monitoring, therefore reducing ICU burden. Older age and chronic respiratory or renal conditions are associated with worse clinical outcomes, while treatment with systemic corticosteroids may have a protective effect on mortality.

    Search related documents:
    Co phrase search for related documents
    • acute ards respiratory distress syndrome and administration dose route: 1
    • acute ards respiratory distress syndrome and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute ards respiratory distress syndrome and admit patient: 1
    • acute ards respiratory distress syndrome and local protocol: 1, 2, 3
    • acute ards respiratory distress syndrome and local treatment protocol: 1
    • acute ards respiratory distress syndrome and long treatment: 1, 2, 3
    • acute ards respiratory distress syndrome and low lymphocyte count: 1, 2
    • acute ards respiratory distress syndrome and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24
    • acute respiratory failure and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory failure and local protocol: 1, 2, 3
    • acute respiratory failure and local treatment protocol: 1
    • acute respiratory failure and long treatment: 1
    • acute respiratory failure and low lymphocyte count: 1
    • acute respiratory failure and low mortality: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17
    • acute respiratory syndrome sars and adequate patient care: 1, 2
    • acute respiratory syndrome sars and administration dose: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25
    • acute respiratory syndrome sars and administration dose route: 1
    • acute respiratory syndrome sars and admission criterion: 1, 2
    • acute respiratory syndrome sars and admission time: 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25